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A rapid development of gadolinium-based nanoparticles is observed due to their 
attractive properties as MRI-positive contrast agents. Indeed, they display high 
relaxivity, adapted biodistribution and passive uptake in the tumor thanks to enhanced 
permeability and retention effect. In addition to these imaging properties, it has been 
recently shown that they can act as effective radiosensitizers under different types of 
irradiation (radiotherapy, neutron therapy or hadron therapy). These new therapeutic 
modalities pave the way to therapy guided by imaging and to personalized medicine.
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Based on a fruitful interaction between vari-
ous scientific fields (chemistry, physics, biol-
ogy and medicine among others), the intense 
research activity devoted to nanotechnolo-
gies led to the development of multifunc-
tional nanoparticles adapted to many differ-
ent applications [1,2] in energy [3], electronics 
[4,5], catalysis [6], agriculture [7], health and 
medicine [8–10]. More specifically, nanopar-
ticles are a class of materials with at least one 
dimension below 100 nm (this range can be 
extended up to 1000 nm in the literature) 
[11,12]. They display interesting properties for 
medical applications as new physical proper-
ties at the nanoscale [13–15]; high surface to 
volume ratio inducing chemical reactivity 
different from bulk materials and possibility 
to gather considerable amounts of imaging or 
therapeutic agents [16]; possibility to gather 
different imaging and/or therapeutic agents 
in a single object for multimodal applications 
[17] and possibility to finely tailor their size, 
shape and surface to modulate their biodis-
tribution [18,19]. Among the different medical 
applications proposed by nanotechnology, 
theranostic (i.e., combination of therapeu-
tic and diagnostic applications) is one of the 
most exciting [20,21]. In this rapidly growing 
field, a particular interest has been focused 
on magnetic nanoparticles [22,23]. In the case 
of magnetic nanoparticles for applications in 
oncology, MRI is the principal modality of 
imaging. It can be coupled with computed 
tomography (CT) [24], fluorescence imag-
ing [25,26], PET [27] or single photon emis-
sion computed tomography (SPECT) [28,29] 
for multimodal imaging. For the therapeutic 
part, magnetic nanoparticles are proposed for 
drug delivery [30], phototherapy [31], photo-
dynamic therapy [32] and radiotherapy [33,34]. 
Radiotherapy is of particular interest in the 
context of theranostic applications because 
it is the most commonly used nonsurgical 
therapy [35] and will benefit greatly from the 
contribution of imaging.
Strategies are now developed to include 
PET/SPECT and/or MRI for the individu-
alization of treatment by radiotherapy, the 
assessment of treatment and the follow-up 
after treatment [36,37]. For such treatments, 
the development of compounds that can 
effectively be used as both imaging agents 
and radiosensitizers (i.e., compounds that 
can enhance the effect of radiotherapy) [38] 
could be a real progress. Most of the radio-
sensitizers tested actually are composed 
of elements with high atomic number (Z) 
which display significantly higher mass 
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energy absorption properties in comparison with soft 
tissues [39,40]. Some classical molecular contrast agents 
based on iodine, gadolinium and some molecular anti-
cancer drugs (e.g., cisplatin) have been already tested 
for radiosensitization [41]. Owing to their capability to 
contain greater amount of high Z elements, radiosensi-
tizing nanoparticles received much attention. The pio-
neering work of Hainfeld et al. [38] revealed that gold 
nanoparticles behave as efficient radiosensitizers due to 
the high atomic number of gold (Z = 79), their easy 
synthesis and relatively safe in vivo behavior [42–44]. 
However promising radiosensitizing nanoparticles can 
also be obtained with other high Z elements. Among 
them, gadolinium (Z = 64) appears very attractive for 
designing nanoparticles, which behave both as radio-
sensitizers and MRI contrast agents. This review aims 
therefore at describing gadolinium-based nanoparticles 
for biomedical applications and more specifically for 
MRI coupled to radiotherapy.
Interest of gadolinium for medicine
Gadolinium is the most well-known lanthanide ele-
ment for medical applications. Its most common oxi-
dation state is +III as other lanthanides; it is considered 
as a hard acid and displays large coordination numbers 
(8–10) [45]. Its use in medicine is directly correlated to 
the development of MRI and to the development of 
contrast agents for this imaging modality. More than 
10 million MRI studies use gadolinium per year [46,47]. 
The choice of gadolinium (III) for MRI applications 
can be explained by its seven unpaired electrons (most 
paramagnetic stable ion) and its slow electronic relax-
ation [48]. The contrast agents based on gadolinium 
are mainly small chelates (like DOTAREM, Guerbet 
or MAGNEVIST®, Bayer Healthcare) used as posi-
tive contrast agents [49]. Unfortunately, small chelates 
 display relatively low relaxivities (Table 1).
Research on gadolinium-based positive contrast 
agent for MRI focused mainly on increasing longi-
tudinal relaxivity. Two major approaches [47,50] have 
been proposed to fulfill this goal: increasing the num-
ber of gadolinium units per object, for example, by 
incorporating the chelates in polymers [51], dendrimers 
[52], nanogels [53] or nanoparticles [54]; and optimizing 
the chemical structures of the chelates, essentially by 
increasing the rotational correlation time [48,55]; this 
can be achieved by enhancing the mass and the rigid-
ity of the structure. Nanotechnologies are particularly 
interesting for these two approaches because many 
gadolinium chelates can be fixed on rigid and heavy 
structures leading to high r
1
 objects.
Besides their use for imaging applications, gadolin-
ium-based compounds are also envisaged for therapeu-
tic applications. In fact, gadolinium displays relatively 
high atomic number (Z = 64) and can thus interact 
with many types of radiations (x- or gamma-rays, 
neutrons, electrons and hadrons, among others) [56]. 
Although this interaction can be used for CT imag-
ing [57], its real interest lies in radiosensitization as 
shown first for molecular compounds. A molecular 
gadolinium texaphyrin complex, motexafin gadolin-
ium (III) is currently undergoing a clinical trial for its 
radiosensitizing properties (Figure 1) [58]. Among the 
different lanthanides, gadolinium is also of particular 
interest for neutron capture therapy due to the high 
neutron capture cross section of nonradioactive 157Gd 
(2.55.105 barns) [59,60].
Despite these advantages for clinical applications, 
gadolinium has to be administrated carefully because 
of the similar ionic radii between gadolinium (III) and 
calcium (II) that can lead to potential replacement of 
calcium by gadolinium in some calcium (II) binding 
sites. As recently emphasized by different publications, 
the release of free gadolinium (III) can be respon-
sible of nephrogenic systemic fibrosis [61,62]. This dis-
ease observed on patients with renal failure that have 
received gadolinium-based contrast agents seems to 
be due to the release of gadolinium from acyclic che-
lates in the acidic conditions of the kidneys. When 
developing new compounds based on gadolinium, a 
specific attention has to be paid on this problem. The 
most used solution is the chelation of gadolinium by 
macrocyclic ligands like, for example, DOTAREM® 
(Guerbet) or ProHance® (Bracco SpA) that are based 
on 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
(DOTA) derivatives.
Nanoparticles made of gadolinium for MRI
Due to the interest of gadolinium essentially for MRI, 
many types of nanoparticles, often multimodal, have 
Table 1. Longitudinal (r1) and transversal (r2) of clinically used gadolinium chelates at 1.0 T.
Contrast agent MAGNEVIST® (Bayer 
Healthcare)
DOTAREM® 
(Guerbet)
OMNISCAN® (GE 
Healthcare) 
Prohance® (Bracco SpA) 
r1 3.4 3.4 3.9 3.7
r2 3.8 4.8 4.3 4.8
Values are stated in units of s-1mM-1.
Data taken from [49].
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Figure 1. Structure of motexafin gadolinium (III). 
Data taken from [58].
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been proposed. Two different types of nanoparticles 
will be discussed in this review. The first one is based 
on architectures already considered for medical appli-
cations on which gadolinium chelates are grafted or 
into it they are loaded in. The second one is constituted 
of hybrid core shell nanoparticles made of a crystalline 
core based on gadolinium or doped with gadolinium.
Nanoparticles functionalized by gadolinium 
chelates
The first interest of grafting gadolinium chelates on 
nanoparticles is to increase the r
1
 per gadolinium ion. 
Many publications focused on the study of the nuclear 
magnetic relaxation dispersion profile and on the opti-
mization of the architectures to obtain higher r
1
 at dif-
ferent magnetic fields. As recently reviewed by Botta 
et al. [55] and Davis et al. [63], gadolinium chelates have 
been grafted on polymers, dendrimers, liposomes, 
micelles, gold or silica nanoparticles. In almost all 
the cases, the same pattern of nuclear magnetic relax-
ation dispersion profile is observed with an important 
enhancement of the relaxivity for the average magnetic 
fields and relaxivity values relatively low at high fields. 
Gadolinium can also be loaded as cargos into adapted 
nano-objects such as mesoporous silica, carbon nano-
tubes or liposomes. In this case, Decuzzi et al. [54] have 
also shown that geometrical confinement of gadolin-
ium chelates can drastically increase their longitudinal 
relaxivity.
In addition to overcome the low relaxivity of gado-
linium chelates, the grafting on nanoparticles signifi-
cantly increases the short half-lives of the chelates in 
the body [64]. However for clinical use, the size of the 
nanoparticles has to be maintained relatively small 
to limit the toxicity due to poor renal clearance. A 
hydrodynamic diameter below 6 nm is generally rec-
ommended to allow complete and exclusive renal 
elimination after intravenous injection as first pub-
lished by Frangioni et al. for quantum dots [65,66]. To 
achieve this, our group has recently proposed a new 
type of nanoparticle called AGuIX, based on a polysi-
loxane core and surrounded by DOTA(Gd) derivatives 
covalently grafted to the inorganic matrix [67]. These 
nanoparticles display hydrodynamic diameter of 3 
nm, mass of 8.5 kDa and longitudinal relaxivity of 6.0 
mM-1.s-1 at 7 T twice the value of the commercial agent 
DOTAREM. The small size is obtained by a top down 
process. First, a gadolinium oxide core is synthesized, 
then encapsulated in a thin polysiloxane shell (sol gel 
process) and finally chelates are covalently grafted to 
the inorganic matrix. During the transfer to water, 
dissolution of the gadolinium oxide core is observed 
and gadolinium is chelated by the ligands leading to 
the final AGuIX nanoparticles. Owing to the pres-
10.2217/NNM.15.30 Nanomedicine (Lond.) (Epub ahead of print)
Figure 2. Distribution of AGuIX nanoparticles in the kidneys. (A) Quantitative mapping of gadolinium and sodium 
in the kidneys as a function of time. (B) Agreement between quantifications by ICP and LIBS. 
ICP: Inductively coupled plasma; LIBS: Laser-induced breakdown spectroscopy. 
Reproduced with permission from [68].
5 
m
in
1 
h
24
 h4 
h
30
 m
in
1 
w
ee
k
Time after injection
G
d
 c
o
n
ce
n
tr
at
io
n
 (
m
M
)
5
4
3
2
1
0
LIBS
ICP
1 mm
5 min 30 min 1 h
4 h 24 h 1 week
Gd (mM) Na (mM)
15
10
5
0 0
10
20
60
future science group
Review    Lux, Sancey, Bianchi, Crémillieux, Roux & Tillement
ence of gadolinium chelates, the excretion mode can 
be monitored by MRI after intravenous injection of 
the nanoparticles in rodents. The data collected from 
MRI clearly showed that the removal of the nanopar-
ticles from body rests on an exclusive renal elimina-
tion. These results have been confirmed by the labeling 
of the nanoparticles by indium-111 and the following 
of the nanoparticles after intravenous (iv.) injection by 
SPECT. Moreover the behavior of the nanoparticles in 
the kidneys has been precisely followed by means of 
laser-induced breakdown spectroscopy performed on 
the tissues after sacrifice of the animals (Figure 2) [68].
Another advantage of AGuIX gadolinium-based 
ultra-small nanoparticles is for lung imaging as 
recently illustrated. In behalf of their hydrodynamic 
diameter close to 3 nm, the nanoparticles can pass 
from the pulmonary airways to the blood circulation 
before elimination by the kidneys. The biodistribution 
can be followed by MRI using ultra-short echo time 
sequences [69]. Acute toxicological study shows almost 
no inflammation after administration of the nanopar-
ticles by the airways [70]. An interesting application of 
the administration of the AGuIX nanoparticles is the 
noninvasive detection of nonsmall-cell lung cancer by 
MRI (Figure 3) [71]. This easy and reproducible method 
of administration permits a better visualization of the 
lung tumors in comparison with intravenous injection. 
When the nanoparticles are administered by airways, 
their passage to the blood circulation is faster from the 
healthy lung tissues than from tumor tissues.
In addition to the development of more effective 
positive contrast agents, some studies are performed 
to develop multimodal imaging agents. Multimodal 
imaging has been developed to propose a better diag-
nostics by combining the advantages of different imag-
ing modalities [72]. Since the beginning of the 2000s, 
different bimodal apparatus are available on the clini-
cal market (PET/CT, SPECT/CT, PET/MRI) or for 
small animals [73]. The arrival on the market of such 
apparatus is accompanied by the development of 
many different multimodal agents and in particular of 
nanoparticles-based contrast agents. Two main types 
of nanoparticles functionalized by gadolinium che-
lates are proposed: some constituted of an inorganic 
core that displays itself imaging properties; and some 
constituted of a matrix functionalized by two or more 
molecular agents displaying different imaging proper-
ties [74]. For the first class of materials, Roux et al. have, 
for example, proposed ultra-small gold nanoparticles 
(hydrodynamic diameter inferior to 10 nm) designed 
10.2217/NNM.15.30www.futuremedicine.com
Figure 3. Detection of lung tumor by MRI. (A) Schematic representation of AGuIX with polysiloxane core and 
DOTA(Gd) grafted to the inorganic matrix. (B–D) UTE MRI axial slices of a lung tumor bearing mice after the 
orotracheal administration of AGuIX (B) 35 days, (C) 49 days and (D) 56 days after the implantation of the tumor. 
Red arrows indicate the tumor. 
For color images please see online at http://www.futuremedicine.com/doi/full/10.2217/nnm.15.30
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for renal elimination that can be used as MRI con-
trast agent due to gadolinium chelates, as CT contrast 
agent due to the gold core [75], and as SPECT imaging 
agent after the labeling by radioisotopes 99mTc and 111In 
[76]. In this case, less than 5% of the injected dose is 
eliminated by the feces in reason of the small size of the 
nanoparticle. For MRI/fluorescence bimodal imaging, 
quantum dots coupled to gadolinium chelates have 
been proposed as illustrated by Hong et al. [77] and by 
Zhu et al. [78]. In each case, fluorescence imaging is per-
mitted by the crystalline core of the quantum dot and 
the magnetic properties by the gadolinium chelates. 
The nanoparticles present low cytotoxicity and inter-
esting properties for cell labeling. Matrix displaying 
no imaging properties (like silica, alumina…) can also 
be used to gather different imaging agents as recently 
illustrated by our group with AGuIX nanoparticles. 
They can be used as imaging agents for MRI and CT, 
due to gadolinium chelates, for fluorescence imaging 
due to covalent grafting of Cyanine 5.5 (a near infrared 
dye) and SPECT imaging due to the labeling of DOTA 
derivative by 111In [79]. On this type of nanoparticles, a 
therapeutic modality can also be added by the addi-
tion of a photosensitizer for photodynamic therapy 
(PDT). The photosensitizer can be an organic mol-
ecule [80] or a complex [81]. When targeting peptides 
such as ATWLPPR toward neuropilin-1 (NRP-1) are 
grafted on the AGuIX nanoparticles designed for PDT, 
10.2217/NNM.15.30 Nanomedicine (Lond.) (Epub ahead of print) future science group
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in vitro results show a photodynamic efficacy of the 
nanoparticles under light irradiation and an effective 
binding toward NRP-1 recombinant proteins. MRI 
suggests an effective accumulation in the tumor after 
intravenous injection in U87 glioblastoma-bearing rats 
(Figure 4) [82].
A large part of the studies currently performed on 
nanoparticles based on gadolinium crystalline core 
deals with gadolinium oxide (Gd
2
O
3
). Roberts et al. 
[83] and Watkin and McDonald [84] were the first to 
show the potential of this nano-object for MRI. Fol-
lowing these preliminary works, our group described a 
reproducible and reliable synthesis of gadolinium oxide 
nanoparticles (size between 1 and 5 nm) by modify-
ing the polyol route [85]. To perform biological experi-
ments, we have functionalized the cores by a polysilox-
ane shell to protect the oxide core and to permit further 
functionalization [86]. The grafting of hydrophilic PEG 
chains to the inorganic matrix leads to stable nanopar-
ticles in water that can be used for in vivo experiments. 
The addition of Cy 5.5 in the polysiloxane matrix for 
fluorescence properties permits to follow the nanopar-
ticles by fluorescence imaging and by MRI after intra-
venous injection in rodents [87]. An attractive biodis-
tribution is observed with effective renal elimination 
that can be changed by modifying the nature of the 
PEG chains grafted to the nanoparticles [19]. Engstrom 
et al. have confirmed the interest of gadolinium oxide 
for MRI [88]. In this case, the gadolinium oxide cores 
are capped by organic acids (citric or dimercaptosuc-
cinic acid) that are used for further functionalization 
by PEG chains but unfortunately no in vivo experi-
ment was performed. More recently, Ding et al. have 
studied the impact on relaxivities of a hydrophobic or a 
hydrophilic coating on gadolinium oxide cores [89]. For 
the hydrophilic coating, they choose polyvinyl pyrrol-
idone (PVP) and for the hydrophobic, they proceed to 
a first coating by hydrophobic oleic acid before add-
ing cetyltrimethylammonium bromide. At 7 T, they 
observe a longitudinal relaxivity of 12.1 mM-1.s-1 and 
Figure 4. GuIX nanoparticles for photodynamic therapy guided by MRI. (A) Binding of untargeted AGuIX nanoparticles (dark red) 
and AGuIX nanoparticles functionalized by ATWLPPR (light red) toward NRP-1 recombinant protein. (B) MTT tests on MDA-MB-231 
cells incubated with AGuIX functionalized by nanoparticles at two concentrations in PS (dark red: 0.1 μM and light red 1 μM) exposed 
to increasing doses of light. (C) MRI images of the brain of U87 glioblastoma bearing rats (1) before injection of nanoparticles and 
(2) after injection of AGuIX functionalized by ATWLPPR. White arrows indicate the tumor. Nanoparticles containing a crystalline core 
constituted or doped by gadolinium. 
O.D.: Optical density. 
Reproduced with permission from [82].
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0.54 mM-1.s-1 per gadolinium for the nanoparticles 
coated by PVP and by oleic acid-cetyltrimethylam-
monium bromide, respectively. The high first value is 
similar to data previously obtained in the literature for 
such structures, the second one can be explained by the 
long hydrophobic chains that prevent the water mol-
ecule approaching the gadolinium of the oxide core. 
The nanoparticles coated by PVP were then used to 
image a tumor bearing mice; a high uptake in kidneys 
and liver is observed and only a low one is observed in 
the tumor.
Some other crystalline structures rich in gadolinium 
have also been proposed and we will focus essentially on 
fluoride (GdF
3
) and carbonate particles (Gd
2
O(CO
3
)
2
.
H
2
O). For GdF
3
 nanoparticles, Van Veggel et al. pro-
posed a synthesis of relatively large nanoparticles by 
reaction of ammonium hydroxide on sodium fluoride 
and gadolinium nitrate in water at 75°C. Citric acid 
(CA) and 2-aminoethylphosphate (AEP) were used to 
coat the nanoparticles leading to diameters of 129.3 
and 51.5 nm for CA and AEP, respectively [90]. Rela-
tively low longitudinal relaxivities are obtained for 
these structures (3.17 and 2.71 mM-1.s-1 for CA and 
AEP, respectively, at 14.1 T). This study confirms that 
not only the gadolinium atoms present at the surface 
of the crystalline core contribute to the relaxation as 
previously shown for gadolinium oxide cores. More 
recently, the same group proposes the synthesis of 
ultra-small NaGdF
4
 nanoparticles to see the influence 
of the size on the longitudinal relaxivity [91]. Four dif-
ferent cores of 2.5, 4, 6.5 and 8 nm have been synthe-
sized and coated by PVP during the transfer to water. 
As expected, the longitudinal relaxivity per gadolin-
ium increases drastically when the size decreases from 
a value of 3.0 mM-1.s-1 to a value of 7.2 mM-1.s-1 per 
gadolinium at 1.5 T. Gadolinium carbonate nanopar-
ticles can be obtained by addition of urea on gadolin-
ium trichloride dissolved in ethylene glycol as shown 
by Kong et al., in this case it is coated by poly(acrylic 
acid) (PAA) [92]. By increasing the quantity of PAA 
added during the synthesis, the authors can monitor 
the size of the nanoparticles, decreasing their size by 
increasing the quantity of PAA (hydrodynamic diam-
eters between 16.9 and 60.7 nm). An interesting lon-
gitudinal relaxivity of 23.4 mM-1.s-1 is observed for the 
nanoparticles displaying a crystalline core of 2.3 nm 
and a total hydrodynamic diameter of 16.9 nm at 3 T. 
In vivo, due to the size of the nanoparticles, an uptake 
in the liver and the spleen is observed but 6 h after 
injection most of the nanoparticles have been cleared 
from the animals.
Gadolinium ions have also been used to dope other 
crystalline structures to render them paramagnetic for 
MRI applications. In particular, gadolinium has been 
used to dope upconverting nanomaterials. Upconver-
sion is a physical process consisting in the absorption of 
two or more photons and leading to the emission of one 
photon at a shorter wavelength. These materials display 
interesting properties for fluorescence imaging due to 
their absorption in the near infrared region that limits 
absorption and auto-fluorescence by the tissues; and 
their high photostability [93]. NaYF
4
 doped by Yb3+ and 
Er3+ displayed for example upconversion luminescence 
with maxima of emission at 520 and 650 nm for an 
excitation at 980 nm. Zhou et al. demonstrate the inter-
est of doping NaYF
4
 inorganic cores by Yb3+, Er3+ and 
Gd3+ to obtain bimodal probes (for fluorescence imag-
ing and MRI). By labeling this nanoparticle by 18F, the 
nanomaterial was therefore followed using PET modal-
ity [94]. In this example, the inorganic core is capped by 
oleic acid and the nanoparticles display hydrodynamic 
diameters of about 28 nm. The r
1
 at 3 T is relatively 
low (0.405 mM-1.s-1). After intravenous injection, most 
of the nanoparticles present a rapid uptake in both 
liver and spleen (70.8 and 55.7% of the injected dose 
per gram at 15 min after injection, respectively). As 
recently shown by Peng et al., this type of nanoparticle 
can also be used for theranostic applications and more 
particularly for PDT with the advantage of an excita-
tion in the near infrared region [93]. To obtain such 
particles, methylene blue has been coupled to NaYF
4
 
inorganic core doped by Yb3+, Er3+ and Gd3+ due to 
important overlap between emission spectrum of the 
inorganic core and the absorption spectrum of the pho-
tosensitizer. Another theranostic application has been 
proposed by Bu et al. by combining photothermal abla-
tion and radiotherapy as two complementary therapeu-
tic modalities [95]. To do this, they use an upconversion 
nanoparticle (NaYbF
4
 inorganic core doped by Er3+ 
and Gd3+) coated by silica that is coupled to ultra-small 
nanoparticles of CuS that act as photothermal agent. 
The whole structure (hydrodynamic diameter close to 
75 nm) can produce significant cytotoxic effect after 
excitation at 980 nm and displays interesting radiosen-
sitizing properties due to the presence of the high Z 
elements. They demonstrate the synergistic effect of 
radiotherapy and photothermal ablation of their mate-
rials after intratumoral injection of the nanoparticles in 
mice bearing 4T
1
 murine breast cancer tumors.
Another example has been proposed by Fernandes 
et al., they synthesized Prussian blue analogues con-
taining interstitial gadolinium cations in the inorganic 
matrix [96]. In this case, the inorganic core is obtained 
by addition of ferrous chloride to potassium hexacya-
noferrate (III) and gadolinium nitrate leading to a size 
of about 33 nm. A longitudinal relaxivity at 3 T of 
38.5 mM-1.s-1 is obtained. The surface is then function-
alized by avidin-Alexa fluor 488 for fluorescence prop-
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erties and by antihuman eotaxin-3 antibody leading to 
important hydrodynamic diameter of 190 nm. In vitro 
experiments show the interest of the nanoparticles to 
target the eosinophilic cell line but unfortunately no 
in vivo experiment has been performed.
Gadolinium-based nanoparticles activated 
by irradiation
In addition to its magnetic characteristics for MRI, 
gadolinium displays also exciting intrinsic therapeutic 
properties under irradiation. Two different types of 
irradiations can be distinguished: neutron irradiation 
and other types of irradiation.
Irradiation by neutrons: neutron capture 
therapy
This type of irradiation has been proposed relatively 
early to treat tumors by neutron capture therapy 
(NCT) [97]. The most studied compounds for NCT 
are 10B containing molecules that lead after neutron 
capture event to the deliverance of 4He2+ and 7Li3+ ions, 
compounds that dissipate their energy at short range 
(∼5–10 μm) causing high damages to cells [98]. Another 
reason why 10B has attracted so much attention is due 
to its high neutron absorption cross section that is at 
least three orders of magnitude higher than those of 
elements present in the tissues (see Table 2) [99–101].
The use of gadolinium for NCT is seriously envisaged 
due to the high capture cross sections of 155Gd and 157Gd 
(see Table 2). Contrary to 10B, the interaction of 155,157Gd 
with neutrons leads to the emission of Auger electrons 
and γ-rays that display cytotoxic effect at short range 
and at long range, respectively [60]. Another advantage 
of gadolinium is that 155Gd and 157Gd are present at rela-
tively high yields naturally (14.8 and 15.65% natural 
abundance, respectively). A relatively high optimal con-
centration of 157Gd in tumor tissues (50–200 μg/g) has 
been determined for efficient therapeutic effect [99,100]. 
Classical MRI contrast agents have been tested for this 
therapeutic modality but they suffer from low uptakes 
in tumor after intravenous injection [100]. To increase 
the quantity of gadolinium delivered to the tumor, dif-
ferent nano-objects have been proposed. For this appli-
cation, core shell nanoparticles made of gadolinium 
oxide core and polysiloxane shell have been synthesized 
[60,88]. Polyethylene glycol chains have been grafted on 
the polysiloxane shell for adapted dispersion in biologi-
cal medium. The nanoparticles were internalized with 
EL4 cells at different concentrations before irradiation 
by neutrons. For 3 Gy irradiation dose, only the cells 
incubated with at least 0.05 mM in gadolinium prior 
to the irradiation died. More recently, Aime’s group 
proposed hydrophobic gadolinium/boron ligands that 
form very stable micelles in aqueous medium [98]. Cel-
lular uptakes were tested on hepG2, B16 and U87 cells. 
The minimum amount of B for NCT has been obtained 
for hepG2 and U87 cells. In vivo experiments were then 
performed on B16 tumor bearing mice after intrave-
nous injection of the micelles. A three times higher sig-
nal is observed in the tumor 4 h after the injection of 
the nanoparticles and a signal is still observed 24 h after 
the injection. Thanks to MRI experiment, a delay of 6 
h after injection was determined to be adapted for neu-
tron irradiation. An important decrease in the tumor 
growth is observed for the animals treated with micelles 
before irradiation. Unfortunately a slow regrowth of the 
tumor occurs at day 15 after irradiation. More recently, 
Yanagie et al. proposed gadolinium chelates (Pro-
Hance) entrapped in liposomes [100]. The distribution 
of liposomes after injection in Col 26 tumor bearing 
mice is then followed by MRI. Irradiation of the ani-
mals is performed between 1 and 2 h after the injection 
of the liposomes. A suppression of the tumor growth 
until 10 days is observed when the neutrons are used in 
combination with the liposomes.
These two in vivo examples emphasize the interest of 
MRI to determine the most suitable moment to apply 
irradiation.
Irradiation by photons: radiosensitization
The principle of radiotherapy is to kill cancerous cells 
using ionizing radiation while sparing as much as 
Table 2. Various capture cross sections of specific nuclides and elements present in the tissues for 
thermal neutrons.
Nuclide Cross-section capture value in barns Element Cross section capture value in barns
10B 3838 H 0.332
149Sm 42,000 C 0.0034
151Eu 5800 N 1.82
155Gd 61,000 O 1.8 × 10-4
157Gd 255,000 Na 0.43
164Dy 1800 Mg 0.053
Reproduced with permission from [101].
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possible the adjacent healthy tissues [44]. To minimize 
the damages to the healthy tissue, one of the strate-
gies that have been developed is the use of chemi-
cal compounds that sensitize the cancerous cells to 
ionizing radiations (radiosensitizer) [102]. Most of the 
works on nanoparticles for radiosensitization have 
been performed on gold nanoparticles thanks to their 
high biocompatibility; easy synthesis and function-
alization; and high density and high atomic number 
of gold [40].
The same type of strategy (i.e., irradiation guided 
by imaging) employed for NCT can be used for 
radiosensitization (Figure 5). Gold nanoparticles are 
efficient CT contrast agents but a better sensitivity 
can be obtained by using MRI. In this context, the 
addition of gadolinium chelates on gold nanopar-
ticles is a real improvement for bimodal imaging 
CT/MRI or for radiotherapy guided by MRI. Some 
groups have developed such types of nanoparticles 
like Roux et al. [75], Mirkin et al. [103] or Penadés et al. 
[104]. In our case, the nanoparticles have been specifi-
cally designed for radiotherapy guided by MRI. As 
previously said, Roux et al. have specifically designed 
their nanoparticles for renal clearance. For the syn-
thesis, they use a method derived from the synthesis 
first described by Brust et al. [105] by reducing gold 
salts (HAuCl
4
.3H
2
O) by NaBH
4
 in presence of a 
dithiolated derivative of the diethylenetriaminepen-
taacetic acid. Gadolinium is then chelated by the 
ligands at the surface of the nanoparticles after addi-
tion of GdCl
3
.6H
2
O. Due to their small hydrody-
namic diameter of 6.6 ± 1.8 nm, an almost exclusive 
renal elimination is observed by MRI [75], scintigra-
phy (after labeling by 99mTc or 111In) [76] or inductive 
coupled plasma-atomic emission spectroscopy. The 
radiosensitizing properties of the nanoparticles have 
been evaluated under MRT (microbeam radiation 
therapy) on two tumor models: osteosarcoma and 
9L glioscarcoma (9LGS) with two different types of 
injection – that is, intratumorally for osteosarcoma 
and iv. for 9LGS. For osteosarcoma, the rats only 
treated by MRT have an increase in lifespan (ILS) 
of 51.8% in comparison with untreated rats. A clear 
increase of the ILS is observed when the MRT is 
performed after the administration of the nanopar-
ticles (117.9%). This value is underestimated because 
the survey of the rats is superior to 50% when the 
rats were sacrificed at day 61 after implantation of 
the osteosarcoma tumor. For the brain tumor bear-
ing rats, the nanoparticles have been injected by iv. 
and their biodistribution has been monitored by 
MRI. Thanks to EPR effect, a positive signal rapidly 
appears in the brain tumor. The higher MRI signal 
was observed between 3 and 7 min after the iv. injec-
tion of the nanoparticles. This moment has been cho-
sen to proceed to the radiotherapy. MRT only lead 
to an increase of the lifespan of 222% and this value 
is extended to 473% when the radiotherapy is per-
formed in presence of the nanoparticles due to the 
radiosensitizing properties of the gold n anoparticles.
As previously described, our group has designed 
another type of nanoparticles specifically for biomedi-
cal applications: AGuIX nanoparticles [35,67,79]. These 
ultra-small nanoparticles made of a polysiloxane core 
and surrounded by gadolinium chelates (size <5 nm) 
have been intensively used for radiosensitization 
in vitro and in vivo.
In vitro, a lot of experimental conditions [35] have 
been tested such as varying energy of the irradiation 
from kiloelectron volts to higher voltages, different 
concentrations of nanoparticles, different types of 
tumor cell lines or the nature of the irradiation. As 
previously described by Butterworth et al. for gold 
nanoparticles [39,43], we observe effective radiosensitiz-
ing effect close to the K-edge of the gadolinium (in the 
kiloelectronvolt region where the photoelectric effect 
predominates) but also in the megaelectronvolt region 
where the Compton diffusion predominates [35]. Pho-
ton irradiation in presence of AGuIX nanoparticles 
has been performed on glioblastoma U-87MG and 
T98G cells [106], on head and neck squamous cell 
carcinoma SQ20B cells [107], on cervical carcinoma 
HeLa cells [108], on prostate DU145 and PC3 cells. In 
each case, significant sensitizing enhancement ratios 
(defined as the survival fraction (SF) ratios of the con-
trol cells (only irradiation) to those of the treated cells 
Figure 5. Schematic representation of radiotherapy 
guided by imaging. 
Reproduced with permission from [35].
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(irradiation in presence of nanoparticles)) have been 
observed (ranging from 1.1 to 2.5). In different stud-
ies, it has been shown that the irradiation in presence 
of nanoparticles induces complex damages. In partic-
ular, during the experiment on SQ20B cells, the shape 
of the SF was plotted against the deposited dose. The 
curve was fitted by the following function:
SF exp D D
2= - +a b6 @
(Equation 1)
α: probability of lethal event; β: sublethal events; 
D: irradiation dose.
Almost no change for β is observed for irradia-
tion in presence of nanoparticles in comparison with 
irradiation only (β varies from 0.05 to 0.03). On the 
contrary, a very significant increase of α is noticed 
when the irradiation is performed in presence of the 
nanoparticles (α varies from 0.04 to 0.5) indicating a 
high level of lethal damages to cells. Interestingly the 
curve of the SF corresponding to irradiation in pres-
ence of nanoparticles is very close to those obtained 
with carbon ion irradiation that indicates probably a 
nanoscale dose deposition. To complete in vitro exper-
iments, irradiation of cells by ions (He2+ and C6+) in 
presence of nanoparticles has been studied [109]. In 
these cases, sensitizing enhancement ratios ranging 
from 1.1 to 1.6 have been obtained confirming the 
interests of the nanoparticles for different types of 
irradiation.
In vivo experiments have also been performed. Even 
if some of them have been done after intratumorally 
injection of the nanoparticles and have shown encour-
aging results with important reduction of the volume 
of the tumors [107], most of the studies have been per-
formed after iv. injection for better clinical relevance. 
A particular attention has been paid to glioblastoma 
in these studies and a first proof of concept has been 
obtained in 2011 for 9LGS bearing rats under MRT 
irradiation [33]. The biodistribution followed by MRI 
clearly shows an uptake in the tumor in the first min-
utes following the administration of the nanoparticles. 
A signal can still be detected 24 h after the injection 
of the AGuIX due to retention in the tumors. For 
untreated animals, a median survival time (MeST) 
of 19 days is observed that is increased to 47 days 
for irradiated animals (ILS = 147%). When the irra-
diation is triggered 5 min after the administration of 
the AGuIX nanoparticles, the MeST is shortened at 
34 days (corresponding to an ILS of only 38%). On 
the contrary, when the irradiation occurs 20 min 
after the iv. injection of the nanoparticles, the MeST 
is increased to 90 days (corresponding to an impres-
sive ILS of 373%). As stated by this experiment, the 
delay between administration of the nanoparticles and 
irradiation has to be chosen carefully. The shortening 
of the MeST at 5 min can be explained by the MRI 
biodistribution that indicates that some nanoparticles 
are still in the healthy brain at this time (blood half-
life >5 min). Contrary to molecular chelates commer-
cially available, the nanoparticles remain for a long 
time in the tumor [110]. This adapted biodistribution 
permits to trigger the irradiation at the most adapted 
moment: when the nanoparticles are cleared from the 
healthy brain tissue but when the concentration of the 
nanoparticles in the tumor is still sufficient for radio-
sensitization. This biodistribution and the nanoscale 
dose deposition observed when nanoparticles are used 
in combination with irradiation explain the important 
increase of ILS. A second way of administration (by the 
airways) of the nanoparticles has been tested for the 
radiotherapy of the lung tumors [34]. The nanoparticles 
have been nebulized in mice bearing H358-Luc biolu-
minescent lung tumors. The nanoparticles labeled by 
a near infrared fluorophore (Cy5.5) have been detected 
by optical imaging and MRI. A good correlation has 
been obtained between the signal observed by MRI or 
optical imaging and the bioluminescence of the tumor 
and the histology [34,71]. The irradiation occurs 24 h 
after the administration of the nanoparticles. The non-
irradiated and the only-irradiated mice display similar 
MeST of 83 and 77 days, respectively. An increase of 
45% of ILS is observed when the irradiation is per-
formed in presence of the nanoparticles (MeST of 112 
days). The development of the adapted sequences for 
the imaging of the lungs in presence of the AGuIX per-
mits a clear delineation of the tumor [71]. It can be used 
to determine the best moment for irradiation and to 
follow up precisely the evolution of the treatment.
Conclusion & future perspective
Nanoparticles based on gadolinium are mainly 
developed for their magnetic properties as positive 
contrast agents for MRI. A large part of the publi-
cations in this field are dedicated to study the influ-
ence of the nanoparticle on the r
1
 and unfortunately 
often few in vivo experiments are performed. Even if 
the nanoparticles can act as efficient contrast agents 
with relaxivities higher than commercially available 
molecules and effective retention in tumors due to 
enhanced permeability and retention effect, their 
development for clinical application might be com-
promised if they present only this imaging modality, 
principally due to the cost of the development of new 
biomedical compounds, but also the potential toxicity 
of nanomaterials itself and to the risk of gadolinium 
release for some of them.
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In our opinion, for a potential use in clinic, MRI 
modality has to be coupled to another modalities either 
for imaging or for therapeutic as illustrated in this 
paper. Multimodal imaging is particularly developed 
due to the recent release on the market of apparatus 
combining two imaging facilities and clearly need-
ing the development of new imaging products and 
nanoparticles are well adapted to incorporate differ-
ent imaging agents. In any cases, an important work 
will have to be performed to assess their nontoxicity 
and their effective elimination of the body after intra-
venous injection. In this context, the development of 
ultra-small nanoparticles that are rapidly eliminated 
by the kidneys seems to be the easiest way.
This paper focused particularly on nanoparticles 
developed for theranostic applications and more pre-
cisely on irradiation guided by MRI. In fact, as first 
shown by Hainfeld et al. [38] for gold nanoparticles, 
nanocompounds based on high atomic number atoms 
can be used as efficient radiosensitizers. They display 
effective interaction with x-rays or secondary species 
that lead to nanoscale dose deposition in the close 
vicinity of the nanoparticle. Gadolinium can also be 
used for radiosensitization even if it presents lower 
atomic number than gold (Z = 64 for gadolinium 
and 79 for gold). MRI modality is a powerful tool to 
localize precisely the tumor and to quantify the con-
centration of radiosensitizer inside it and inside the 
surrounding healthy tissues before irradiation. It per-
mits to determine the most adapted moment to acti-
vate the nanoparticles by irradiation after intravenous 
injection and can lead to the concept of personalized 
medicine.
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Executive summary
Interest & risk of gadolinium for medicine
•	 More than 10 million MRI studies per year use gadolinium due to its seven unpaired electron and its slow 
relaxation rate.
•	 Gadolinium can act as an effective radiosensitizer in reason of its high atomic number that permits effective 
interaction with x-rays or other types of irradiation.
•	 It can also be used for neutron capture therapy due to high neutron absorption cross section of gadolinium 
155 and 157.
•	 To avoid any toxicity, no release of free gadolinium is allowed because of nephrogenic systemic fibrosis.
Main types of gadolinium-based nanoparticles
•	 Two main types of nanoparticles are described in this paper. Nanoparticles already considered for medical 
applications on which gadolinium chelates are grafted or into it they are loaded in and hybrid core shell 
nanoparticles made of a crystalline core based on gadolinium or doped with gadolinium (Gd2O3, GdF3, 
NaYF4:Er
3, Yb3+ and Gd3+ among others).
Applications of gadolinium-based nanoparticles
•	 Many architectures are developed to increase the longitudinal relaxivity per gadolinium and per object for 
application as positive contrast agent in MRI.
•	 Many studies are devoted to multimodal imaging by addition on gadolinium-based nanoparticles of imaging 
agents for scintigraphy, fluorescence imaging or computed tomography.
•	 Growing number of publications focused on theranostic applications, gadolinium acting as MRI contrast agent 
and as therapeutic agent for neutron capture therapy or radiosensitization. Chemotherapy, photothermal 
ablation or photodynamic therapy necessitates the addition of other therapeutic agents.
Radiosensitization in presence of gadolinium-based nanoparticles
•	 Nanostructuration of gadolinium leads to high nanoscale dose deposition in close vicinity of the nanoparticle 
under irradiation.
•	 Radiosensitization with ultra-small gadolinium-based nanoparticles leads in vitro to complex damages.
Interest of radiotherapy guided by imaging
•	 Possibility to follow the biodistribution of the nanoparticles by MRI.
•	 Determination of the best moment for radiotherapy by imaging leading to personalized medicine.
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